http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2764443-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e0c3817a9a11c70076dd3ce4f863e4f4 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-407 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7053 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7069 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-32 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-407 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-18 |
| filingDate | 2017-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-01-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf314cd4e4f0b572cfc8eeb4d9d89ea4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fdc3246b2c0d6757a159100cf55643a0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_913298edf7eedadaa4c5e5731819fcf4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_52074325d36d9d53cb915bf8a30ef341 |
| publicationDate | 2022-01-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2764443-C2 |
| titleOfInvention | Transdermal therapeutic system containing azenapine and polysiloxane or polyisobutylene |
| abstract | FIELD: medicine.SUBSTANCE: invention relates to options of a transdermal therapeutic system for transdermal delivery of azenapine and a method for obtaining a layer containing azenapine for use in the transdermal therapeutic system. The transdermal therapeutic system contains a self-adhesive layered structure containing the therapeutically effective amount of azenapine. The self-adhesive layered structure contains: A) substrate; B) a layer containing azenapine, containing: 1. azenapine in the form of a free base; and 2. polymer selected from a group consisting of polysiloxanes in the amount of more than 50% by weight per the total weight of the layer containing azenapine; and C) optionally, an additional layer contacting with the skin. The layer containing azenapine contains a crystallization inhibitor in the amount from 0.5 to 10% by weight per the total weight of the layer containing azenapineEFFECT: obtaining a transdermal therapeutic system of a matrix type for transdermal azenapine injection, providing a penetration speed that is sufficient for achieving a therapeutically effective dose.15 cl, 13 ex, 13 tbl, 13 dwg |
| priorityDate | 2016-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 117.